Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 8—August 2005

Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

Ran D. Balicer*†Comments to Author , Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
Author affiliations: *Ministry of Health, Jerusalem, Israel; †Ben-Gurion University of the Negev, Be'er-Sheva, Israel

Main Article

Table 2

Cost-benefit ratios of antiviral utilization strategies*

Strategy Cost-benefit ratio, relative to nonintervention
All costs to economy Direct healthcare costs
NI No intervention (base case) Ref. Ref.
1a Therapeutic use (all patients) 2.44 0.30
1b Therapeutic use (limited to patients at high risk) 3.68 1.51
2a Preexposure long-term prophylaxis of entire population 0.38 0.04
2b Preexposure long-term prophylaxis, limited to high-risk population 0.37 0.10
3a Postexposure short-term prophylaxis for all close contacts ("ring prophylaxis"), including treatment of index patients 2.49 0.27

*Ref., reference value of zero divided by zero.

Main Article

Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.